Active, not recruitingPhase 3NCT06492291
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
Studying Disorder of lipid metabolism
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- Enlicitide Decanoate(drug)
- Enrollment
- 3000 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2028
Study locations (30)
- Alliance for Multispecialty Research, LLC ( Site 0027), Daphne, Alabama, United States
- G&L Research ( Site 0035), Foley, Alabama, United States
- Synexus Clinical Research US, Inc.-Synexus Clinical Research US, Inc - Central Phoenix ( Site 0048), Phoenix, Arizona, United States
- National Heart Institute-Research ( Site 0029), Beverly Hills, California, United States
- Clinical Trials Research ( Site 0054), Sacramento, California, United States
- Velocity Clinical Research, Banning ( Site 0023), San Bernardino, California, United States
- Emerson Clinical Research Institute ( Site 0017), Washington D.C., District of Columbia, United States
- Excel Medical Clinical Trials ( Site 0010), Boca Raton, Florida, United States
- Alliance for Multispecialty Research, LLC ( Site 0037), Doral, Florida, United States
- Alliance for Multispecialty Research, LLC ( Site 0056), Fort Myers, Florida, United States
- Velocity Clinical Research, Hallandale Beach ( Site 0053), Hallandale, Florida, United States
- Jacksonville Center for Clinical Research ( Site 0025), Jacksonville, Florida, United States
- South Broward Research ( Site 0012), Miramar, Florida, United States
- Progressive Medical Research ( Site 0033), Port Orange, Florida, United States
- Clinical Research Trials of Florida ( Site 0006), Tampa, Florida, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06492291 on ClinicalTrials.govOther trials for Disorder of lipid metabolism
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06695325Convenient Home Access for Routine Monitoring in Diabetes (Charm-D Study)Tameside General Hospital
- RECRUITINGPHASE1NCT06947304Evaluation of Miricorilant on Liver Fat in Patients With MASLDCorcept Therapeutics
- ACTIVE NOT RECRUITINGPHASE2NCT07028749Study of MAR001 in Adults With Elevated Triglycerides and Remnant CholesterolMarea Therapeutics
- ENROLLING BY INVITATIONPHASE4NCT06845345Effect of an Early Time Restricted Eating Mediterranean Diet Compared to Naltrexone/Bupropion on Liver Fibrosis in People With Cardiometabolic Risk Factors in a Hospital Outpatient Clinic (MEDFAST-study)Carmen Dietvorst
- RECRUITINGPHASE3NCT06643130Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and DyslipidemiaJW Pharmaceutical
- ENROLLING BY INVITATIONNANCT06822621Functional Cereal Products and Contribution to the Regulation of Metabolism and Obesity-induced Chronic Low-grade Inflammation.Harokopio University
- RECRUITINGNCT06206759Vitamin C Administration and Triglycerides Level in Critical Care PatientsMeir Medical Center
- RECRUITINGNCT06383208Cardiovascular-Renal Adverse Prognosis Assessment System for Coronary Heart Disease With Chronic Kidney Disease Based on MetabolomicsChina-Japan Friendship Hospital